Company Filing History:
Years Active: 2025
Title: Christopher R. Corbeil: Innovating in Cancer Treatment
Introduction
Christopher R. Corbeil, located in Dollard-des-Ormeaux, Canada, is a notable inventor in the field of biomedical innovation, particularly known for his work in cancer treatment. With one patent to his name, he has made significant strides in the development of targeted therapies for solid tumors. His innovative approach leverages the unique pH characteristics of tumor environments to enhance treatment efficacy.
Latest Patents
Corbeil's patent, titled "Antibody Variants with pH-Dependent Antigen Binding for Selective Targeting of Solid Tumors," reflects his pioneering work in the design of anti-Her2 antibodies. This invention is designed to bind to Her2-expressing cells in a pH-dependent manner, boasting low affinity at physiological pH, typical of normal cells, and high affinity at slightly acidic pH, characteristic of solid tumors. The antibodies not only inhibit the growth of tumor spheroids comparably to the established anti-Her2 antibody Herceptin but also demonstrate a remarkable selectivity that is maintained upon conjugation to cytotoxic drugs. This innovation offers promising methods for treating and detecting solid tumors, along with the ability to capture the Her-2 ectodomain effectively.
Career Highlights
Christopher R. Corbeil is currently employed at the National Research Council of Canada, where he contributes to groundbreaking research and advancements in biotechnology. His work has positioned him as a key figure in the development of selective treatment strategies for cancer therapies.
Collaborations
Throughout his career, Corbeil has collaborated with esteemed colleagues, including Traian Sulea and Jason Baardsnes. Their combined expertise has fostered a rich environment for innovation and has amplified the potential impacts of their research outcomes.
Conclusion
Christopher R. Corbeil's contributions to the field of cancer treatment through innovative antibody design signify a meaningful advancement in medical science. His dedication to developing pH-selective therapies for solid tumors showcases the transformative potential of targeted treatments in improving patient outcomes. As he continues his research at the National Research Council of Canada, the future looks promising for further innovations under his guidance.